Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
This study has been terminated.
( The collaborator, Genentech, stopped supplying the study drug to the site. )
Study NCT01225146   Information provided by Greater Houston Retina Research

First Received on October 14, 2010.   Last Updated on November 26, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ischemia
Retinal Vein Occlusion
Pathologic Processes
Retinal Diseases
Eye Diseases
More general conditions related to this trial
Cardiovascular Diseases
Embolism and Thrombosis
Thrombosis
Vascular Diseases
Venous Thrombosis
Interventions listed in this trial
ranibizumab
Sponsors listed in this trial
David M. Brown, M.D.
Genentech


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services